Sharp, an expert in contract packaging, clinical supply services and small-scale sterile manufacturing, is expanding its Macungie, PA site in North America to increase its production capacity for sterile injectables secondary packaging.
 
The expansion will offer increased capacity for secondary packaging activities including Vial Labeling, Pre-Filled Syringe (PFS) assembly and labeling, Autoinjector/Pen assembly & labeling and Injectables Kitting and Cartoning for pharmaceutical and biotech companies.
 
The expansion adds 157,500 sq. ft. of open space to create a 315,000-square-foot facility, bringing Sharp’s total global footprint to more than 1.7 million square feet.
 
Jeff Benedict, Chief Commercial Officer at Sharp, commented: “Demand for sterile injectable medicines has skyrocketed over the last few years due to increased investment in the biologics industry across all therapeutic categories, rare and orphan disease therapies, and blockbuster GLP-1 agonists.”
 
Kevin Orfan, CEO of Sharp, added: “With this expansion, the Macungie site will double in size allowing Sharp to offer additional capacity and capabilities for our biopharma clients for complex biologics and small-molecule injectable medicines.”
 
Plans for the site include the construction and fit-out of new packaging suites, ambient warehouse space, cold storage rooms as well as equipment and technology to support assembly, labelling and packaging of injectables. Once the GMP infrastructure is in place, Sharp anticipates adding 75-100 colleagues to its team.